"As recognized by ASCO's guideline update, recent studies have shown that extending tamoxifen treatment for 10 years is associated with better outcomes, however, we still need better tools to identify who those patients are," said
This new study analyzed 668 and 1065 patients from the original NSABP B-14 and B-28 trials, respectively. Median follow-up of 13.9 years (B-14) and 11.2 years (B-28) determined that the Oncotype DX Recurrence Score results were significantly associated with distant recurrence after five years in patients whose tumors had high estrogen receptor expression. Specifically, in the NSABP B-14 patients, the association of the continuous Recurrence Score with distant recurrence after five years in the higher ER patients was significant (p=0.004) after adjustment for age, grade and tumor size. The results suggest that extending tamoxifen beyond five years may be most beneficial in patients with high and intermediate Recurrence Scores with higher quantitative ER expression. Conversely, patients with low Recurrence Score results would be expected to have limited benefit from extended tamoxifen beyond five years due to much lower risk for late distant recurrence.
"Since its introduction a decade ago, the Oncotype DX breast cancer test has helped patients and their physicians around the world make better informed treatment decisions," said
Future announcements will highlight results from additional Oncotype DX studies in breast, prostate and renal cancers, demonstrating the unique, practice-changing impact of the Oncotype DX tests worldwide.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's intent to continue its investment to capture significant opportunities in the international and prostate markets; the company's expectations regarding reporting study results; the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the ability of any potential tests the company may develop to optimize cancer treatment; and the ability of the company to develop and commercialize additional tests in the future. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests and expand into new markets domestically and internationally; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts; the company's ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's report on Form 10-Q for the period ended March 31, 2014. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
News Provided by Acquire Media